Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: A controlled propensity-matched analysis of a French multicenter cohort

Neuro-Oncology

Volumn 17, Issue 12, 2015, Pages 1609-1619

  Pallud, Johan ^a,b,c,d   Audureau, Etienne ^e,f   Noel, Georges ^g,h   Corns, Robert ⁱ   Lechapt Zalcman, Emmanuele ^j,k,l,m   Duntze, Julien ⁿ   Pavlov, Vladislav ^a,b   Guyotat, Jacques ^o   Hieu, Phong Dam ^p   Le Reste, Pierre Jean ^q   Faillot, Thierry ^r   Litre, Claude Fabien ⁿ   Desse, Nicolas ^s   Petit, Antoine ^t   Emery, Evelyne ^j   Voirin, Jimmy ^u,v   Peltier, Johann ^w   Caire, Francois ^x   Vignes, Jean Rodolphe ^y   Barat, Jean Luc ^z   Langlois, Olivier ^aa   Dezamis, Edouard ^a,b   Parraga, Eduardo ^a,b   Zanello, Marc ^a,b   Nader, Edmond ^ab   Lefranc, Michel ^w   Bauchet, Luc ^d,ac   Devaux, Bertrand ^a,b   Menei, Philippe ^z   Metellus, Philippe ^ab,ad   De Neuro Oncologie, Club ^a   more..

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT PASTEUR   (France)

^d Reseau d'Etude des Gliomes REG   (France)

^e HENRI MONDOR HOSPITAL   (France)

^f UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^g CENTRE PAUL STRAUSS   (France)

^h UNIVERSITÉ DE STRASBOURG   (France)

ⁱ LEEDS GENERAL INFIRMARY   (United Kingdom)

^j CAEN UNIVERSITY HOSPITAL   (France)

^k CNRS   (France)

^l UNIVERSITÉ DE CAEN   (France)

^m DIF   (France)

ⁿ HÔPITAL MAISON BLANCHE   (France)

^o HÔPITAL NEUROLOGIQUE   (France)

^p UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^q PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^r BEAUJON HOSPITAL   (France)

^s Sainte Anne University Military Hospital   (France)

^t UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^u Pasteur Hospital   (France)

^v HÔPITAL DE HAUTEPIERRE   (France)

^w AMIENS UNIVERSITY HOSPITAL   (France)

^x LIMOGES UNIVERSITY HOSPITAL   (France)

^y HÔPITAL PELLEGRIN   (France)

^z Hospital Clairval   (France)

^aa ROUEN UNIVERSITY HOSPITAL   (France)

^ab ANGERS UNIVERSITY HOSPITAL   (France)

^ac GUI DE CHAULIAC HOSPITAL   (France)

^ad University of the Mediterranean Aix Marseille II   (France)

more..

Author keywords

Carmustine wafers; Chemoradiotherapy; Glioblastoma; Surgery; Survival

Indexed keywords

BEVACIZUMAB; CARMUSTINE; CORTICOSTEROID; TEMOZOLOMIDE; ALKYLATING AGENT;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CASE CONTROL STUDY; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG SAFETY; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MULTICENTER STUDY; NEUROSURGERY; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PROGRESSION FREE SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; VERY ELDERLY; ADJUVANT CHEMOTHERAPY; BRAIN NEOPLASMS; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; CARMUSTINE; CHEMOTHERAPY, ADJUVANT; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84958544011     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov126     Document Type: Article

References (32)

1. Louis DN, Carvenee WK. WHO Classification of Tumours of the Central Nervous System. Lyon: IARC press, 2007.
2. Ricard D, Idbaih A, Ducray F, et al. Primary brain tumours in adults. Lancet. 2012;379(9830):1984-1996.
3. Marko NF, Weil RJ, Schroeder JL, et al. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. J Clin Oncol. 2014;32(8): 774-782.
4. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459-466.
5. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
6. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709-722.
7. Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699-708.
8. Noël G, Huchet A, Feuvret L, et al. Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy. J Neurooncol. 2012;109(1):167-175.
9. Mcgirt MJ, Than KD, Weingart JD, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583-588.
10. Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003;5(2):79-88.
11. Westphal M, Ram Z, Riddle V, et al. Gliadelw wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta Neurochir (Wien). 2006;148(3):269-275.
12. Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery. 1997; 41(1):44-49.
13. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol. 2008;15(10): 2887-2893.
14. Duntze J, Litré C-F, Eap C, et al. Implanted carmustine wafers followed by concomitant radiochemotherapy to treat newly diagnosed malignant gliomas: prospective, observational, multicenter study on 92 cases. Ann Surg Oncol. 2012;20(6): 2065-2072.
15. Affronti ML, Heery CR, Herndon JE, et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009;115(15): 3501-3511.
16. Menei P, Metellus P, Parot-Schinkel E, et al. Biodegradable carmustine wafers (Gliadel) alone or in combination with chemoradiotherapy: the French experience. Ann Surg Oncol. 2010;17(7):1740-1746.
17. La Rocca RV, Mehdorn HM. Localized BCNU chemotherapy and the multimodal management of malignant glioma. Curr Med Res Opin. 2009;25(1):149-160.
18. Pan E, Mitchell SB, Tsai JS. A retrospective study of the safety of BCNU wafers with concurrent temozolomide and radiotherapy and adjuvant temozolomide for newly diagnosed glioblastoma patients. J Neurooncol. 2008;88(3):353-357.
19. Pavlov V, Page P, Abi-Lahoud G, et al. Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas. Br J Neurosurgery. 2015; doi:10.3109/02688697.2015.1012051.
20. Mirimanoff R-O, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24(16):2563-2569.
21. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198.
22. Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) working group. Neurosurgery. 2012;70(1):234-244.
23. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology working group. J Clin Oncol. 2010;28(11):1963-1972.
24. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8(7):1277-1280.
25. Austin PC. An Introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399-424.
26. Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10(2): 150-161.
27. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387-398.
28. Bock HC, Puchner MJA, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience. Neurosurg Rev. 2010;33(4):441-449.
29. Noël G, Schott R, Froelich S, et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. Int J Radiat Oncol Biol Phys. 2012;82(2):749-755.
30. Miglierini P, Bouchekoua M, Rousseau B, et al. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity. Clin Neurol Neurosurg. 2012;114(9):1222-1225.
31. Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7(5):392-401.
32. De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012;30(20):2559-2565.